Brief: CSL Says No Longer Targeting Completion Of Demerger In FY2026
27/10/2025 22:35
Oct 28 (Reuters) - CSL Ltd CSL.AX: FINANCIAL YEAR 2026 REVENUE GROWTH OUTLOOK TO 2-3% SEES FINANCIAL YEAR 2026 NPATA GROWTH 4-7% NO LONGER TARGETING COMPLETION OF A DEMERGER IN FINANCIAL YEAR 2026 ADVANCING WITH PREVIOUSLY PROPOSED DEMERGER TIMING WILL NOT FULLY CAPTURE SEQIRUS' VALUE POTENTIAL Further company coverage: CSL.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Csl
See all newsEU Commission opens antitrust probe into Sanofi's flu vaccine campaign (updated)
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
US military requires flu vaccine for some after outbreak in Texas training center
Corrected: BUZZ-Australian healthcare stocks hit a six-week high, acting as a primary hedge on ASX